Startseite
SL

Suzhou Lixin Pharmaceutical Co., Ltd

371
26
8
4.2(50)

Über das Unternehmen

  • Firmenname (rechtlich): Suzhou Lixin Pharmaceutical Co., Ltd
  • Registrierungsland: China
  • Adresse: 21 Tangxi Road, Suzhou New District, Suzhou 215151, Jiangsu, China
  • Gründungsjahr: 2000
Beschreibung:

Suzhou Lixin Pharmaceutical Co., Ltd, established in 2000, is a manufacturer of active pharmaceutical ingredients operating GMP facilities in Suzhou, Jiangsu and Zibo, Shandong, with a product range covering oncology, cardiovascular, and antiviral APIs including Semaglutide, Tenofovir Alafenamide Fumarate, Esomeprazole, Bortezomib, Oxaliplatin, Capecitabine, Ticagrelor, Clopidogrel Bisulfate, and Gefitinib, among many other intermediates and chiral building blocks. The company has built its regulatory track record over more than two decades: it obtained its first new drug certificate in 2009, passed a US FDA on-site inspection in 2010, secured its first CEP in 2012, passed EMA/EDQM inspection in 2016, and stood up a second GMP site in Shandong in 2017 that earned its own CEP in 2022. It holds dozens of patents, including international PCT filings across the US, Europe, and China, and offers CRO, CMO, and CDMO contract services backed by dedicated production lines, tight control from starting materials through to finished product, and an experienced regulatory, patent, and sales team serving customers across North America, Western and Eastern Europe, and Asia.

Geschäftsaktivitäten

Pharmazeutische Wirkstoffe (API)

API-HerstellerHersteller

Laborchemikalien, Lösungsmittel & Referenzstandards

Hersteller

Pharmazeutische Chemikalien

Hersteller
Absatzmärkte
Hauptprodukte/-dienstleistungen

Unsere Produkte & Dienstleistungen

Certifications

Chinese GMP

US FDA

EDQM

EMA

DMF of API to US FDA

CEP-Zertifikat

GMP certificates

GMP management system and continuously improves and pursues excellence

GMP workshops and professional APIs production lines

FDA

Filter:
Sortieren nach:

    Keine Kommentare verfügbar.